7%) had automated PD. During the one-year study period, none received immuno-suppressants and none had active TB. All denied TB exposure. Based on the dynamic change of QFT-GIT results in the 204 patients (Fig. 1), the QFT-GIT1 results were positive in 45 (22.1%) patients, negative in 155 (75.9%), and indeterminate in 4 (2.0%). In QFT-GIT2 and QFT-GIT3, the positive rate decreased to 19.6% ([24 + 16]/204) and 14.2% ([19 + 2+2 + 6]/204),
respectively. The reversion (positive to negative) rate was 44.4% (20/45) from QFT-GIT1 to QFT-GIT2 and 47.5% ([5 + 14]/[24 + 16]) from QFT-GIT2 to QFT-GIT3 (overall 45.9%, 95% CI: 37.0–54.8%). On the other hand, the conversion (negative to positive) rate was 10.3% (16/155) and selleck chemicals 5.1% ([2 + 6]/[20 + 137]) from QFT-GIT1 to QFT-GIT2 and from QFT-GIT2 to QFT-GIT3, respectively (overall 7.7%, 95% CI: 5.2–10.2%). The reversion rate in the next six months was 87.5% (14/16, 95% CI: 71.3–100%) for a recent converter and
20.8% (5/24, 95% CI: 4.6–37.1%) for persistent positive patients (remote positivity). As regards QFT-GIT response at each time-point, results >2.0 IU/ml correlated with persistent positive pattern rather than the variable pattern or persistent negative pattern (Fig. 2). Among QFT-GIT1-positive patients, there was no difference in age, sex, co-morbidity, and laboratory data between those with reversion and those with persistent QFT-GIT positivity, except that the former had lower QFT-GIT response (calculated by IFN-γ level in the supernatant of TB-antigen tube minus that of negative control tube) (Table 1). SCH727965 price Among the QFT-GIT2-positive patients regardless of QFT-GIT1 results, QFT-GIT2 response was significantly higher in the QFT-GIT3-positive than in the QFT-GIT3-negative patients (1.85 vs. 0.57 IU/ml, p < 0.001). The clinical characteristics were similar between those with conversion and persistent QFT-GIT negative patients, except that the former had higher isothipendyl proportion of prior TB history (9% vs. 2%, p = 0.042) ( Table 1). The response in positive control of QFT-GIT1 was
similar regardless subsequent reversion or conversion. The positive controls of the indeterminate results had a significant lower response than those of positive and negative results (0.16 vs. 9.43 vs. 8.74 IU/ml, p < 0.001). Patients with different QFT-GIT1 responses had different conversion and reversion rates (Table 2). The proportion of conversion was higher in patients with QFT-GIT1 around 0.25–0.34 IU/ml compared to those with QFT-GIT1 <0.25 IU/ml (p = 0.065 and p = 0.002 for the change in QFT-GIT2 and QFT-GIT3, respectively). The proportion of reversion in patients with QFT-GIT1 0.35–0.80 IU/ml was higher than those with QFT-GIT1 >0.80 IU/ml (p = 0.001 and p < 0.001 for QFT-GIT2 and QFT-GIT3, respectively). There was no significant difference in clinical characteristics between patients with QFT-GIT1 within 0.25–0.80 IU/ml and the rest.
Related posts:
- Fesoterodine high tumor grade a finding that was also observed in the GeparQuinto study
- Fludarabine Fludara study period was significantly increased with cant
- Platelet count was determined using an automated cell counter, an
- P2X Receptor patients in the OPD group did not have a CR in the delayed period
- Studies have proven the 5-year survival fee was 55% for patients with favorable